What is the survival rate for Non-Small Cell Lung Cancer by stage

Survival Rates for Non-Small Cell Lung Cancer by Stage

I'll break down what we know about NSCLC survival rates based on current medical evidence. It's important to understand that these are statistical averages — your individual situation depends on many factors specific to you.

Overall NSCLC Survival Statistics

According to the NCCN Guidelines for Non-Small Cell Lung Cancer, the overall 5-year relative survival rate for adenocarcinoma (the most common type of NSCLC) is 32.2%. However, this varies significantly by stage and other factors.

The good news: Survival rates have improved substantially. From 2015-2016, the 2-year survival for NSCLC was 42%, compared to 34% from 2009-2010. This improvement reflects advances in targeted therapies and immunotherapies.

Survival by Biomarker Status

Here's where it gets more encouraging — if you have specific genetic mutations or biomarkers, survival rates can be much higher:

According to NCCN Guidelines:

• 5-year survival rates range from 15% to 62.5%, depending on the biomarker
• Patients with EGFR mutations, ALK rearrangements, or other targetable mutations often have significantly better outcomes with targeted therapy
• Patients eligible for immunotherapy (checkpoint inhibitors) also show improved survival

Examples of Better Outcomes:

• EGFR-mutated advanced NSCLC: Studies show 5-year survival rates around 50% or higher with osimertinib (a targeted therapy)
• ALK-rearranged NSCLC: 5-year survival rates around 50% with ALK inhibitors
• High PD-L1 expression (immunotherapy-responsive): 5-year survival rates around 50% with pembrolizumab

Why Biomarker Testing Matters

This is critical: The NCCN Guidelines emphasize that biomarker testing is essential to guide treatment selection and ensure optimal outcomes in patients with NSCLC, particularly for those with advanced or metastatic disease.

Your specific survival outlook depends heavily on:

• Stage (how far the cancer has spread)
• Histology (cell type — adenocarcinoma, squamous cell, etc.)
• Genetic mutations (EGFR, ALK, BRAF, ROS1, etc.)
• PD-L1 expression (indicates immunotherapy responsiveness)
• Overall health and performance status
• Treatment received

Important Context

These survival statistics represent patients treated with various approaches. Your individual prognosis could be better or worse depending on:

• Whether your cancer has targetable mutations
• Your response to treatment
• Your overall health
• Access to newer therapies

Questions to Ask Your Oncologist

To understand YOUR specific situation better:

1. What is my specific stage and histology? (This gives you a baseline)
2. Have all relevant biomarkers been tested? (EGFR, ALK, BRAF, ROS1, PD-L1, MSI-H/dMMR, NTRK)
3. Based on my biomarkers, what are the treatment options and expected outcomes?
4. What is the median progression-free survival (time before cancer grows) with my recommended treatment?
5. Are there clinical trials I might be eligible for?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines for Non-Small Cell Lung Cancer, Version 8.2025
• NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, 2024
• NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, 2024